Skip to main content

Advertisement

SpringerLink
Log in

Current Trends in GPCR Allostery

  • Published:
The Journal of Membrane Biology Aims and scope Submit manuscript

Abstract

GPCRs remain the most important drug target comprising ~ 34% of the Food and Drug Administration (FDA)-approved drugs. In modern pharmacology of GPCRs, modulating receptor signaling based on requirement of a specific disorder is of immense interest. Classical drugs targeting orthosteric sites in GPCRs completely block the binding of endogenous ligand and consequently inhibit all important signals from a GPCR. Some of many signals elicited by the endogenous ligands may play vital role and inhibiting these may also cause severe side effects in the long run. However, allosteric drugs can modulate GPCR signaling without blocking the endogenous ligand binding. Therefore, allosteric drugs can maintain beneficial signaling of the receptor and prevent unwanted side effects. In this chapter, we will discuss GPCR crystal structures solved with allosteric ligands, advantages of allosteric drugs, and allosteric drugs which are in clinical use or trials.

Graphic Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Abdel-Magid F (2015) Allosteric modulators: an emerging concept in drug discovery. ACS Med Chem Lett 6:104–107

    Article  PubMed  PubMed Central  Google Scholar 

  • Acharya A, Coop JE, Polli AD, Mackerell Jr (2011) Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des 7:10–22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Balakrishnan A, Polli JE (2006) Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm 3:223–230

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Butkiewicz M et al (2019) Identification of novel allosteric modulators of metabotropic glutamate receptor subtype 5 acting at site distinct from 2-methyl-6-(phenylethynyl)-pyridine binding. ACS Chem Neurosci 10:3427–3436

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cabral-Marques O et al (2018) GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nat Commun 9:5224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Christopher JA et al (2015) Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). J Med Chem 58:6653–6666

    Article  CAS  PubMed  Google Scholar 

  • Christopoulos A et al (2014) International Union of basic and clinical pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol Rev 66:918–947

    Article  CAS  PubMed  Google Scholar 

  • Davenport P et al (2013) International Union of basic and clinical pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 65:967–986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • de Graaf C, Rein C, Piwnica D, Giordanetto F, Rognan D (2011) Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors. ChemMedChem 6:2159–2169

    Article  PubMed  Google Scholar 

  • Deshpande I et al (2019) Smoothened stimulation by membrane sterols drives Hedgehog pathway activity. Nature 571:284–288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dore S et al (2014) Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 511:557–562

    Article  CAS  PubMed  Google Scholar 

  • Gacasan SB, Baker DL, Parrill AL (2017) G protein-coupled receptors: the evolution of structural insight. AIMS Biophys 4:491–527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Grover K (2013) Use of allosteric targets in the discovery of safer drugs. Med Princ Pract 22:418–426

    Article  PubMed  PubMed Central  Google Scholar 

  • Hauser S, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE (2017) Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 16:829–842

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hauser S et al (2018) Pharmacogenomics of GPCR drug targets. Cell 172:41-54e19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hu GM, Mai TL, Chen CM (2017) Visualizing the GPCR network: classification and evolution. Sci Rep 7:15495

    Article  PubMed  PubMed Central  Google Scholar 

  • Huang Z et al (2011) ASD: a comprehensive database of allosteric proteins and modulators. Nucleic Acids Res 39:D663-669

    Article  CAS  PubMed  Google Scholar 

  • Huang Z et al (2014) ASD v2.0: updated content and novel features focusing on allosteric regulation. Nucleic Acids Res 42:D510-516

    Article  CAS  PubMed  Google Scholar 

  • Kenakin T, Strachan RT (2018) PAM-antagonists: a better way to block pathological receptor signaling? Trends Pharmacol Sci 39:748–765

    Article  CAS  PubMed  Google Scholar 

  • Koehl A et al (2019) Structural insights into the activation of metabotropic glutamate receptors. Nature 566:79–84

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kooistra AJ et al (2021) GPCRdb in 2021: integrating GPCR sequence, structure and function. Nucleic Acids Res 49(D1):D335–D343. https://doi.org/10.1093/nar/gkaa1080

    Article  CAS  PubMed  Google Scholar 

  • Korczynska M et al (2018) Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor. Proc Natl Acad Sci USA 115:E2419–E2428

    Article  CAS  PubMed  Google Scholar 

  • Krishnan A, Nijmeijer S, de Graaf C, Schioth HB (2016) Classification, nomenclature, and structural aspects of adhesion GPCRs. Handb Exp Pharmacol 234:15–41

    Article  CAS  PubMed  Google Scholar 

  • Kruse C et al (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101–106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kurogi Y, Guner OF (2001) Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr Med Chem 8:1035–1055

    Article  CAS  PubMed  Google Scholar 

  • Lamim Ribeiro JM, Filizola M (2019) Allostery in G protein-coupled receptors investigated by molecular dynamics simulations. Curr Opin Struct Biol 55:121–128

    Article  CAS  PubMed  Google Scholar 

  • Liang YL et al (2020) Structure and dynamics of adrenomedullin receptors AM1 and AM2 reveal key mechanisms in the control of receptor phenotype by receptor activity-modifying proteins. ACS Pharmacol Transl Sci 3:263–284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu X et al (2017) Mechanism of intracellular allosteric beta2AR antagonist revealed by X-ray crystal structure. Nature 548:480–484

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu H et al (2018) Orthosteric and allosteric action of the C5a receptor antagonists. Nat Struct Mol Biol 25:472–481

    Article  CAS  PubMed  Google Scholar 

  • Liu X et al (2020a) An allosteric modulator binds to a conformational hub in the beta2 adrenergic receptor. Nat Chem Biol 16:749–755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu X et al (2020b) Unraveling allosteric landscapes of allosterome with ASD. Nucleic Acids Res 48:D394–D401

    CAS  PubMed  Google Scholar 

  • Lu J et al (2017) Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40. Nat Struct Mol Biol 24:570–577

    Article  CAS  PubMed  Google Scholar 

  • Luckmann M et al (2019) Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1. Proc Natl Acad Sci USA 116:7123–7128

    Article  PubMed  Google Scholar 

  • Maeda S, Qu Q, Robertson MJ, Skiniotis G, Kobilka BK (2019) Structures of the M1 and M2 muscarinic acetylcholine receptor/G-protein complexes. Science 364:552–557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meyer C, Heidecke H (2018) Antibodies against GPCR. Front Biosci 23:2177–2194

    Article  CAS  Google Scholar 

  • Oldham WM, Hamm HE (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9:60–71

    Article  CAS  PubMed  Google Scholar 

  • Schulze W, Kunze R, Wallukat G (2005) Pathophysiological role of autoantibodies against G-protein-coupled receptors in the cardiovascular system. Exp Clin Cardiol 10:170–172

    CAS  PubMed  PubMed Central  Google Scholar 

  • Shao Z et al (2019) Structure of an allosteric modulator bound to the CB1 cannabinoid receptor. Nat Chem Biol 15:1199–1205

    Article  CAS  PubMed  Google Scholar 

  • Shen Q et al (2016) ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks. Nucleic Acids Res 44:D527-535

    Article  CAS  PubMed  Google Scholar 

  • Sriram K, Insel PA (2018) G Protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol Pharmacol 93:251–258

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Takakura Y, Hashida M (1995) Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit Rev Oncol Hematol 18:207–231

    Article  CAS  PubMed  Google Scholar 

  • Taylor M et al (2010) Using ligand-based virtual screening to allosterically stabilize the activated state of a GPCR. Chem Biol Drug Des 75:325–332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tolle-Sander S, Lentz KA, Maeda DY, Coop A, Polli JE (2004) Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm 1:40–48

    Article  CAS  PubMed  Google Scholar 

  • Vaidehi N, Bhattacharya S (2016) Allosteric communication pipelines in G-protein-coupled receptors. Curr Opin Pharmacol 30:76–83

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wakefield E, Mason JS, Vajda S, Keseru GM (2019) Analysis of tractable allosteric sites in G protein-coupled receptors. Sci Rep 9:6180

    Article  PubMed  PubMed Central  Google Scholar 

  • Wenthur J, Gentry PR, Mathews TP, Lindsley CW (2014) Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol 54:165–184

    Article  CAS  PubMed  Google Scholar 

  • Wingler LM, McMahon C, Staus DP, Lefkowitz RJ, Kruse AC (2019) Distinctive activation mechanism for angiotensin receptor revealed by a synthetic nanobody. Cell 176:479-490e412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu H et al (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344:58–64

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu F et al (2020) Full-length human GLP-1 receptor structure without orthosteric ligands. Nat Commun 11:1272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xia Y, Kellems RE (2011) Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol 7:659–674

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu Y et al (2019) Mutagenesis facilitated crystallization of GLP-1R. IUCrJ 6:996–1006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yu W, MacKerell AD Jr (2017) Computer-aided drug design methods. Methods Mol Biol 1520:85–106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zheng Y et al (2016) Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature 540:458–461

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhou Q et al (2019) Common activation mechanism of class A GPCRs. Elife 8:50279

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by National Institutes of Health Grants, HL132351 and R01HL142091, and LRI Chair’s Innovative Research Award to S.S.K. We thank Russell Desnoyer for his comments and suggestions on this chapter.

Author information

Authors and Affiliations

  1. Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Khuraijam Dhanachandra Singh & Sadashiva S. Karnik

Authors
  1. Khuraijam Dhanachandra Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sadashiva S. Karnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sadashiva S. Karnik.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, K.D., Karnik, S.S. Current Trends in GPCR Allostery. J Membrane Biol 254, 293–300 (2021). https://doi.org/10.1007/s00232-020-00167-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00232-020-00167-6

Keywords

Search

Navigation